Conference Highlights
Prostate
cancer is an abnormal and uncontrolled growth of cells found in prostate gland.
Causes of prostate cancer include age, genetics, diet, medication, obesity and
sexually transmitted diseases. The market from 2005 to 2020 covering 21 major
drugs categorized into four therapies; namely hormonal therapy, chemotherapy,
immunotherapy, and targeted therapy. Out of 21 drugs, 13 are currently
commercially available in the market and 8 are in pipeline.
Breast
Cancer is the most common cause of death in women. Deaths from breast could be
avoided if cancer screening rates increased among women at risk. This market is
expected to rise at a compound annual growth rate (CAGR) of 2.5% and reach $24
billion by 2018.
Blood
malignancies are forms of cancer that begins in the cells of blood-forming
tissue, such as the bone marrow, or in the cells of the immune system.
According to market study, the market of haematological malignancies is
expressed to show steady growth rate during the forecast period from 2014 –
2020. The global blood disorders market segment is estimated at $49.3 billion
in 2012 and is expected to reach nearly $64.7 billion by 2018.
Colorectal
cancer is a term for cancer that starts in either the colon or the rectum.
Colorectal Cancer (CRC) research market value will increase at a moderate
Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4
billion by 2020.
Radiology
is a science dealing with x-rays or nuclear radiation, especially for
diagnostic and medical uses. It involves the study of science of radioactive
substances and high-energy radiations. Radiology helps in detecting and
diagnosing various diseases and abnormalities in various body organs. Medical
images are produced using x-rays or using radioactive substances or using sound
waves. Radiology and Oncology 2018 will
provide 2 days of discussion on methods related to management and quality
improvement of Cancer and as well as to explore the new ideas on global scale
and other minimally invasive treatments.
No comments:
Post a Comment